{"rows":[{"id":5821,"title":"Psychedelics as potent anti-inflammatory therapeutics","authors":"Charles D. Nichols","journal":"Neuropharmacology","publication_date":"2022-08-22","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109232","pubmed_id":"36007854","openalex_id":"https://openalex.org/W4293282462","source_url":"https://doi.org/10.1016/j.neuropharm.2022.109232","substance_tags":"psilocybin","topic_tags":"Pharmacology,Mechanism of Action,Consciousness,Review Article,Inflammation","study_type":"Review Article","source_name":"OpenAlex","publication_status":"published","date_added":"2026-08-09 08:25:41","last_checked":"2026-08-09 08:25:41","bibtex":null,"source_record_id":"PMID:36007854","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/j.neuropharm.2022.109232","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"PMID:36007854","source_url":"https://doi.org/10.1016/j.neuropharm.2022.109232","doi":"10.1016/j.neuropharm.2022.109232","pmid":"36007854","publication_date":"2022-08-22","importer_version":"2.1.3","text_redistributed":false}},{"id":2618,"title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.","authors":"Halberstadt AL, Geyer MA","journal":"Neuropharmacology","publication_date":"2011-09-01","publication_year":2011,"doi":"10.1016/j.neuropharm.2011.01.017","pubmed_id":"21256140","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/21256140/","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology,Review Article,Drug Interactions","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:21256140","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/21256140/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:21256140","source_url":"https://pubmed.ncbi.nlm.nih.gov/21256140/","doi":"10.1016/j.neuropharm.2011.01.017","pmid":"21256140","publication_date":"2011-09-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2378,"title":"TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT receptor pharmacological tool, or none of the above?","authors":"Di Giovanni G, De Deurwaerdère P","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2017.10.004","pubmed_id":"28987938","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/28987938/","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Receptor Pharmacology,Review Article,Animal Study","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:25","bibtex":null,"source_record_id":"PMID:28987938","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/28987938/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:28987938","source_url":"https://pubmed.ncbi.nlm.nih.gov/28987938/","doi":"10.1016/j.neuropharm.2017.10.004","pmid":"28987938","publication_date":"2018-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2377,"title":"Psychiatry & the psychedelic drugs. Past, present & future.","authors":"Rucker JJH, Iliff J, Nutt DJ","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2017.12.040","pubmed_id":"29284138","openalex_id":"https://openalex.org/W2781316183","source_url":"https://pubmed.ncbi.nlm.nih.gov/29284138/","substance_tags":"psilocybin","topic_tags":"Aging,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:25","bibtex":null,"source_record_id":"PMID:29284138","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/29284138/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:29284138","source_url":"https://pubmed.ncbi.nlm.nih.gov/29284138/","doi":"10.1016/j.neuropharm.2017.12.040","pmid":"29284138","publication_date":"2018-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2376,"title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.","authors":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2017.12.041","pubmed_id":"29288686","openalex_id":"https://openalex.org/W2781340150","source_url":"https://pubmed.ncbi.nlm.nih.gov/29288686/","substance_tags":"psilocybin","topic_tags":"Depression,Brain Imaging,Emotional Processing,Randomized Controlled Trial,Treatment-Resistant Depression","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:25","bibtex":null,"source_record_id":"PMID:29288686","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/29288686/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:29288686","source_url":"https://pubmed.ncbi.nlm.nih.gov/29288686/","doi":"10.1016/j.neuropharm.2017.12.041","pmid":"29288686","publication_date":"2018-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2375,"title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.","authors":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2018.05.012","pubmed_id":"29753748","openalex_id":"https://openalex.org/W2806419184","source_url":"https://pubmed.ncbi.nlm.nih.gov/29753748/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Addiction,Receptor Pharmacology,Review Article,Cancer Patients,Safety","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:25","bibtex":null,"source_record_id":"PMID:29753748","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/29753748/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:29753748","source_url":"https://pubmed.ncbi.nlm.nih.gov/29753748/","doi":"10.1016/j.neuropharm.2018.05.012","pmid":"29753748","publication_date":"2018-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2280,"title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.","authors":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD","journal":"Neuropharmacology","publication_date":"2020-05-01","publication_year":2020,"doi":"10.1016/j.neuropharm.2019.107933","pubmed_id":"31917152","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/31917152/","substance_tags":"psilocybin","topic_tags":"Pharmacology,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:24","bibtex":null,"source_record_id":"PMID:31917152","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/31917152/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:31917152","source_url":"https://pubmed.ncbi.nlm.nih.gov/31917152/","doi":"10.1016/j.neuropharm.2019.107933","pmid":"31917152","publication_date":"2020-05-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2051,"title":"Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain","authors":"Spain Aisling, Howarth Clare, Khrapitchev Alexandre A., Sharp Trevor, Sibson Nicola R., Martin Chris","journal":"Neuropharmacology","publication_date":"2015-12-01","publication_year":2015,"doi":"10.1016/j.neuropharm.2015.07.018","pubmed_id":"26192543","openalex_id":"https://openalex.org/W878533373","source_url":"https://doi.org/10.1016/j.neuropharm.2015.07.018","substance_tags":"psilocin","topic_tags":"Brain Imaging,Receptor Pharmacology,Aging,Animal Study","study_type":"Animal Study","source_name":"Crossref","publication_status":"published","date_added":"2026-07-01 06:52:05","last_checked":"2026-08-09 08:28:50","bibtex":null,"source_record_id":"PMID:26192543","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1016/j.neuropharm.2015.07.018","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:26192543","source_url":"https://doi.org/10.1016/j.neuropharm.2015.07.018","doi":"10.1016/j.neuropharm.2015.07.018","pmid":"26192543","publication_date":"2015-12-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1714,"title":"Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.","authors":"Ortiz CE, Dourron HM, Sweat NW, Garcia-Romeu A, MacCarthy S, Anderson BT, Hendricks PS","journal":"Neuropharmacology","publication_date":"2022-08-15","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109127","pubmed_id":"35577136","openalex_id":"https://openalex.org/W4280579129","source_url":"https://pubmed.ncbi.nlm.nih.gov/35577136/","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:19","bibtex":null,"source_record_id":"PMID:35577136","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35577136/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35577136","source_url":"https://pubmed.ncbi.nlm.nih.gov/35577136/","doi":"10.1016/j.neuropharm.2022.109127","pmid":"35577136","publication_date":"2022-08-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1703,"title":"Psychedelics as preventive treatment in headache and chronic pain disorders.","authors":"Schindler EAD","journal":"Neuropharmacology","publication_date":"2022-09-01","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109166","pubmed_id":"35718005","openalex_id":"https://openalex.org/W4282962482","source_url":"https://pubmed.ncbi.nlm.nih.gov/35718005/","substance_tags":"psilocybin","topic_tags":"Chronic Pain,Headache / Migraine,Mechanism of Action,Review Article,Safety","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:19","bibtex":null,"source_record_id":"PMID:35718005","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35718005/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35718005","source_url":"https://pubmed.ncbi.nlm.nih.gov/35718005/","doi":"10.1016/j.neuropharm.2022.109166","pmid":"35718005","publication_date":"2022-09-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1650,"title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.","authors":"Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ","journal":"Neuropharmacology","publication_date":"2022-11-01","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109220","pubmed_id":"35987353","openalex_id":"https://openalex.org/W4292136326","source_url":"https://pubmed.ncbi.nlm.nih.gov/35987353/","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Consciousness,Spirituality,Safety,Abuse Liability","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:18","bibtex":null,"source_record_id":"PMID:35987353","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35987353/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35987353","source_url":"https://pubmed.ncbi.nlm.nih.gov/35987353/","doi":"10.1016/j.neuropharm.2022.109220","pmid":"35987353","publication_date":"2022-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1639,"title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.","authors":"Belouin SJ, Averill LA, Henningfield JE, Xenakis SN, Donato I, Grob CS, Berger A, Magar V, Danforth AL, Anderson BT","journal":"Neuropharmacology","publication_date":"2022-11-15","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109214","pubmed_id":"35973601","openalex_id":"https://openalex.org/W4291227674","source_url":"https://pubmed.ncbi.nlm.nih.gov/35973601/","substance_tags":"psilocybin","topic_tags":"Review Article","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:18","bibtex":null,"source_record_id":"PMID:35973601","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35973601/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35973601","source_url":"https://pubmed.ncbi.nlm.nih.gov/35973601/","doi":"10.1016/j.neuropharm.2022.109214","pmid":"35973601","publication_date":"2022-11-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1605,"title":"Mescaline: The forgotten psychedelic.","authors":"Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ","journal":"Neuropharmacology","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109294","pubmed_id":"36252614","openalex_id":"https://openalex.org/W4306169038","source_url":"https://pubmed.ncbi.nlm.nih.gov/36252614/","substance_tags":"psilocybin","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology,Wellbeing,Review Article,Animal Study","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:18","bibtex":null,"source_record_id":"PMID:36252614","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36252614/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36252614","source_url":"https://pubmed.ncbi.nlm.nih.gov/36252614/","doi":"10.1016/j.neuropharm.2022.109294","pmid":"36252614","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1559,"title":"Considerations in assessing the abuse potential of psychedelics during drug development.","authors":"Calderon SN, Bonson KR, Reissig CJ, Lloyd JM, Galati S, Chiapperino D","journal":"Neuropharmacology","publication_date":"2023-02-15","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109352","pubmed_id":"36455646","openalex_id":"https://openalex.org/W4310170729","source_url":"https://pubmed.ncbi.nlm.nih.gov/36455646/","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36455646","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36455646/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36455646","source_url":"https://pubmed.ncbi.nlm.nih.gov/36455646/","doi":"10.1016/j.neuropharm.2022.109352","pmid":"36455646","publication_date":"2023-02-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1549,"title":"Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.","authors":"Heal DJ, Gosden J, Smith SL, Atterwill CK","journal":"Neuropharmacology","publication_date":"2023-03-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109375","pubmed_id":"36529260","openalex_id":"https://openalex.org/W4311766514","source_url":"https://pubmed.ncbi.nlm.nih.gov/36529260/","substance_tags":"psilocybin","topic_tags":"Pharmacology,Receptor Pharmacology,Animal Study,Safety,Toxicity,Drug Interactions,Inflammation","study_type":"Animal Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36529260","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36529260/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36529260","source_url":"https://pubmed.ncbi.nlm.nih.gov/36529260/","doi":"10.1016/j.neuropharm.2022.109375","pmid":"36529260","publication_date":"2023-03-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1529,"title":"The varieties of psychedelic law.","authors":"Marks M","journal":"Neuropharmacology","publication_date":"2023-03-15","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109399","pubmed_id":"36565855","openalex_id":"https://openalex.org/W4312058527","source_url":"https://pubmed.ncbi.nlm.nih.gov/36565855/","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36565855","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36565855/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36565855","source_url":"https://pubmed.ncbi.nlm.nih.gov/36565855/","doi":"10.1016/j.neuropharm.2022.109399","pmid":"36565855","publication_date":"2023-03-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1528,"title":"Canalization and plasticity in psychopathology.","authors":"Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ","journal":"Neuropharmacology","publication_date":"2023-03-15","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109398","pubmed_id":"36584883","openalex_id":"https://openalex.org/W4313251651","source_url":"https://pubmed.ncbi.nlm.nih.gov/36584883/","substance_tags":"psilocybin","topic_tags":"Neuroplasticity,Mechanism of Action","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36584883","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36584883/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36584883","source_url":"https://pubmed.ncbi.nlm.nih.gov/36584883/","doi":"10.1016/j.neuropharm.2022.109398","pmid":"36584883","publication_date":"2023-03-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1514,"title":"Psychedelics: Science sabotaged by Social Media.","authors":"Sellers EM, Romach MK","journal":"Neuropharmacology","publication_date":"2023-04-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2023.109426","pubmed_id":"36693562","openalex_id":"https://openalex.org/W4317677634","source_url":"https://pubmed.ncbi.nlm.nih.gov/36693562/","substance_tags":"psilocybin","topic_tags":"Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36693562","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36693562/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36693562","source_url":"https://pubmed.ncbi.nlm.nih.gov/36693562/","doi":"10.1016/j.neuropharm.2023.109426","pmid":"36693562","publication_date":"2023-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1477,"title":"National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.","authors":"Xi D, Berger A, Shurtleff D, Zia FZ, Belouin S","journal":"Neuropharmacology","publication_date":"2023-06-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2023.109467","pubmed_id":"36858149","openalex_id":"https://openalex.org/W4322505390","source_url":"https://pubmed.ncbi.nlm.nih.gov/36858149/","substance_tags":"psilocybin","topic_tags":"Pharmacology","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:15","bibtex":null,"source_record_id":"PMID:36858149","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36858149/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36858149","source_url":"https://pubmed.ncbi.nlm.nih.gov/36858149/","doi":"10.1016/j.neuropharm.2023.109467","pmid":"36858149","publication_date":"2023-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1465,"title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.","authors":"Wulff AB, Nichols CD, Thompson SM","journal":"Neuropharmacology","publication_date":"2023-06-15","publication_year":2023,"doi":"10.1016/j.neuropharm.2023.109504","pubmed_id":"36921889","openalex_id":"https://openalex.org/W4324045013","source_url":"https://pubmed.ncbi.nlm.nih.gov/36921889/","substance_tags":"psilocybin","topic_tags":"Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Animal Study,Treatment-Resistant Depression,Inflammation","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:15","bibtex":null,"source_record_id":"PMID:36921889","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36921889/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36921889","source_url":"https://pubmed.ncbi.nlm.nih.gov/36921889/","doi":"10.1016/j.neuropharm.2023.109504","pmid":"36921889","publication_date":"2023-06-15","importer_version":"2.1.3","text_redistributed":false}}],"total":31,"page":1,"per_page":20,"pages":2,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Neuropharmacology","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}